Cargando…
Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity
SIMPLE SUMMARY: The transition of cells with epithelial characteristics to those with mesenchymal characteristics (termed EMT) facilitates breast cancer invasive capacity. The EMT program can also contribute to immunosuppressive and immunoevasive properties, altering susceptibility to immune cell re...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496737/ https://www.ncbi.nlm.nih.gov/pubmed/36139558 http://dx.doi.org/10.3390/cancers14184397 |
_version_ | 1784794342755401728 |
---|---|
author | Camp, Faye A. Brunetti, Tonya M. Williams, Michelle M. Christenson, Jessica L. Sreekanth, Varsha Costello, James C. Hay, Zachary L. Z. Kedl, Ross M. Richer, Jennifer K. Slansky, Jill E. |
author_facet | Camp, Faye A. Brunetti, Tonya M. Williams, Michelle M. Christenson, Jessica L. Sreekanth, Varsha Costello, James C. Hay, Zachary L. Z. Kedl, Ross M. Richer, Jennifer K. Slansky, Jill E. |
author_sort | Camp, Faye A. |
collection | PubMed |
description | SIMPLE SUMMARY: The transition of cells with epithelial characteristics to those with mesenchymal characteristics (termed EMT) facilitates breast cancer invasive capacity. The EMT program can also contribute to immunosuppressive and immunoevasive properties, altering susceptibility to immune cell recognition and killing. The goal of our study was to manipulate EMT to reveal potential neoantigens that might affect the ability of tumor cells to circumvent immune escape and/or be utilized as an anticancer vaccine to kill cancer cells exhibiting the cellular plasticity that permits therapy resistance and metastatic progression. We identified potential neoantigens resulting from EMT-associated altered gene expression and alternative splicing events and observed increased immunogenicity and susceptibility to killing of the more epithelial-like cancer cells. Although the tested peptides did not protect from tumor growth, a limited number of predicted neoantigens derived from intron retention events were tested. In the future, refined prediction programs may facilitate exciting antigen discoveries. ABSTRACT: Antigenic differences formed by alterations in gene expression and alternative splicing are predicted in breast cancer cells undergoing epithelial to mesenchymal transition (EMT) and the reverse plasticity known as MET. How these antigenic differences impact immune interactions and the degree to which they can be exploited to enhance immune responses against mesenchymal cells is not fully understood. We utilized a master microRNA regulator of EMT to alter mesenchymal-like EO771 mammary carcinoma cells to a more epithelial phenotype. A computational approach was used to identify neoantigens derived from the resultant differentially expressed somatic variants (SNV) and alternative splicing events (neojunctions). Using whole cell vaccines and peptide-based vaccines, we find superior cytotoxicity against the more-epithelial cells and explore the potential of neojunction-derived antigens to elicit T cell responses through experiments designed to validate the computationally predicted neoantigens. Overall, results identify EMT-associated splicing factors common to both mouse and human breast cancer cells as well as immunogenic SNV- and neojunction-derived neoantigens in mammary carcinoma cells. |
format | Online Article Text |
id | pubmed-9496737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94967372022-09-23 Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity Camp, Faye A. Brunetti, Tonya M. Williams, Michelle M. Christenson, Jessica L. Sreekanth, Varsha Costello, James C. Hay, Zachary L. Z. Kedl, Ross M. Richer, Jennifer K. Slansky, Jill E. Cancers (Basel) Article SIMPLE SUMMARY: The transition of cells with epithelial characteristics to those with mesenchymal characteristics (termed EMT) facilitates breast cancer invasive capacity. The EMT program can also contribute to immunosuppressive and immunoevasive properties, altering susceptibility to immune cell recognition and killing. The goal of our study was to manipulate EMT to reveal potential neoantigens that might affect the ability of tumor cells to circumvent immune escape and/or be utilized as an anticancer vaccine to kill cancer cells exhibiting the cellular plasticity that permits therapy resistance and metastatic progression. We identified potential neoantigens resulting from EMT-associated altered gene expression and alternative splicing events and observed increased immunogenicity and susceptibility to killing of the more epithelial-like cancer cells. Although the tested peptides did not protect from tumor growth, a limited number of predicted neoantigens derived from intron retention events were tested. In the future, refined prediction programs may facilitate exciting antigen discoveries. ABSTRACT: Antigenic differences formed by alterations in gene expression and alternative splicing are predicted in breast cancer cells undergoing epithelial to mesenchymal transition (EMT) and the reverse plasticity known as MET. How these antigenic differences impact immune interactions and the degree to which they can be exploited to enhance immune responses against mesenchymal cells is not fully understood. We utilized a master microRNA regulator of EMT to alter mesenchymal-like EO771 mammary carcinoma cells to a more epithelial phenotype. A computational approach was used to identify neoantigens derived from the resultant differentially expressed somatic variants (SNV) and alternative splicing events (neojunctions). Using whole cell vaccines and peptide-based vaccines, we find superior cytotoxicity against the more-epithelial cells and explore the potential of neojunction-derived antigens to elicit T cell responses through experiments designed to validate the computationally predicted neoantigens. Overall, results identify EMT-associated splicing factors common to both mouse and human breast cancer cells as well as immunogenic SNV- and neojunction-derived neoantigens in mammary carcinoma cells. MDPI 2022-09-09 /pmc/articles/PMC9496737/ /pubmed/36139558 http://dx.doi.org/10.3390/cancers14184397 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Camp, Faye A. Brunetti, Tonya M. Williams, Michelle M. Christenson, Jessica L. Sreekanth, Varsha Costello, James C. Hay, Zachary L. Z. Kedl, Ross M. Richer, Jennifer K. Slansky, Jill E. Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity |
title | Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity |
title_full | Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity |
title_fullStr | Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity |
title_full_unstemmed | Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity |
title_short | Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8(+) T Cell Immunity |
title_sort | antigens expressed by breast cancer cells undergoing emt stimulate cytotoxic cd8(+) t cell immunity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496737/ https://www.ncbi.nlm.nih.gov/pubmed/36139558 http://dx.doi.org/10.3390/cancers14184397 |
work_keys_str_mv | AT campfayea antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT brunettitonyam antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT williamsmichellem antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT christensonjessical antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT sreekanthvarsha antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT costellojamesc antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT hayzacharylz antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT kedlrossm antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT richerjenniferk antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity AT slanskyjille antigensexpressedbybreastcancercellsundergoingemtstimulatecytotoxiccd8tcellimmunity |